Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer

被引：10

作者：

Iwata, Hiroji ^{[1
]}

Masuda, Norikazu ^{[2
]}

Kim, Sung-Bae ^{[3
]}

Inoue, Kenichi ^{[4
]}

Rai, Yoshiaki ^{[5
]}

Fujita, Takashi ^{[6
]}

Chiu, Joanne ^{[7
]}

Ohtani, Shoichiro ^{[8
]}

Takahashi, Masato ^{[9
]}

Miyaki, Toshiko ^{[10
]}

Lu, Yen-Shen ^{[11
]}

Xu, Binghe ^{[12
,13
]}

Yap, Yoon Sim ^{[14
]}

Bustam, Anita ^{[15
]}

Yao, Bin ^{[16
]}

Zhang, Bo ^{[16
]}

Bryce, Richard ^{[16
]}

Chan, Arlene ^{[17
,18
]}

机构：

[1] Aichi Canc Ctr, Dept Breast Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan

[2] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Breast Oncol, Osaka 5400006, Japan

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, KS013, Seoul, South Korea

[4] Saitama Canc Ctr, Div Breast Oncol, Saitama 3620806, Japan

[5] Hakuaikai Med Corp, Sagara Hosp, Kagoshima 8920845, Japan

[6] Jichi Med Univ Hosp, Dept Breast Oncol, Shimotsuke, Tochigi 3290498, Japan

[7] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China

[8] Hiroshima City Hosp, Dept Breast Surg, Hiroshima 7308518, Japan

[9] Natl Hosp Org Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido 0630005, Japan

[10] Chiba Canc Ctr, Div Breast Surg, Chiba 2608717, Japan

[11] Natl Taiwan Univ Hosp, Taipei, Taiwan

[12] Chinese Acad Med Sci, Dept Med Oncol, Natl Canc Ctr, Canc Hosp, Beijing 100021, Peoples R China

[13] Peking Union Med Coll, Beijing 100021, Peoples R China

[14] Natl Canc Ctr Singapore, Div Med Oncol, Singapore 169610, Singapore

[15] Univ Malaya, Med Ctr, Clin Oncol Unit, Kuala Lumpur 50603, Malaysia

[16] Puma Biotechnol Inc, Los Angeles, CA 90024 USA

[17] Breast Canc Res Ctr WA, Perth, WA, Australia

[18] Curtin Univ, Perth, WA, Australia

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 21期

关键词：

Asia; early stage breast cancer; efficacy; extended adjuvant therapy; HER2; neratinib; safety; tyrosine kinase inhibitor; DOUBLE-BLIND; HKI-272; EXTENET; SAFETY;

D O I：

10.2217/fon-2019-0143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240mg/day or placebo for 1year after trastuzumab-based adjuvant therapy. Results: A total of 341 patients were from Asia (neratinib, n=165; placebo, n=176). 2-year invasive disease-free survival rates were 92.8 and 90.8% with neratinib and placebo, respectively (HR: 0.70; 95% CI: 0.31-1.55), and 5-year rates were 91.9 and 87.2%, respectively (HR: 0.57; 95% CI: 0.27-1.13). Diarrhea was the most common adverse event with neratinib. Conclusion: Extended adjuvant therapy with neratinib reduces disease recurrences in Asian women with HER2-positive breast cancer. Trial registration: Clinicaltrials.gov NCT00878709.

引用

页码：2489 / 2501

页数：13

共 50 条

[31] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
Yamshiro, Hiroyasu
Iwata, Hiroji
Masuda, Norikazu
Yamamoto, Naohito
Nishimura, Reiki
Ohtani, Shoichiro
Sato, Nobuki
Takahashi, Masato
Kamio, Takako
Yamazaki, Kosuke
Saito, Tsuyoshi
Kato, Makoto
Lee, Tecchuu
Ohno, Shinji
Kuroi, Katsumasa
Takano, Toshimi
Takada, Masahiro
Yasuno, Shinji
Morita, Satoshi
Toi, Masakazu
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
[32] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
Hiroyasu Yamshiro
Hiroji Iwata
Norikazu Masuda
Naohito Yamamoto
Reiki Nishimura
Shoichiro Ohtani
Nobuki Sato
Masato Takahashi
Takako Kamio
Kosuke Yamazaki
Tsuyoshi Saito
Makoto Kato
Tecchuu Lee
Shinji Ohno
Katsumasa Kuroi
Toshimi Takano
Masahiro Takada
Shinji Yasuno
Satoshi Morita
Masakazu Toi
International Journal of Clinical Oncology, 2015, 20 : 709 - 722
[33] Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine
Khanmammadov, Nijat
Dogan, Izzet
Khishigsuren, Bayarmaa
Azizy, Abdulmunir
Saip, Pinar
Aydiner, Adnan
MEDICINE, 2025, 104 (06)
[34] Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada
Younis, T.
Lee, A.
Coombes, M. E.
Bouganim, N.
Becker, D.
Revil, C.
Jhuti, G. S.
CURRENT ONCOLOGY, 2020, 27 (06) : E578 - E589
[35] Duration of extended adjuvant therapy with neratinib in early-stage HER2+breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.
Gnant, Michael
Iwata, Hiroji
Bashford, Anna Elizabeth
Separovic, Robert
Murias, Adolfo
Vicente, Elena
Means-Powell, Julie Ann
Mayer, Ingrid A.
Senecal, Francis Mark
Hui, Rina
De Boer, Richard H.
Chiu, Joanne
Armstrong, Anne
Ruiz, Amparo
Bryce, Richard
Ye, Yining
Chan, Arlene
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[36] Neratinib in HER2-Positive Breast Cancer Patients
Paranjpe, Rutugandha
Basatneh, Dima
Tao, Gabriel
De Angelis, Carmine
Noormohammed, Sobia
Ekinci, Ekim
Abughosh, Susan
Ghose, Romi
Trivedi, Meghana V.
ANNALS OF PHARMACOTHERAPY, 2019, 53 (06) : 612 - 620
[37] POTENTIAL COST-EFFECTIVENESS OF NERATINIB FOLLOWING TRASTUZUMAB THERAPY FOR TREATMENT OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
Schwartz, N. R.
Steuten, L.
Babigumira, J. B.
Roth, J. A.
VALUE IN HEALTH, 2018, 21 : S28 - S28
[38] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
Haq, Bushra
Geyer, Charles E.
WOMENS HEALTH, 2009, 5 (02) : 135 - 147
[39] CARDIOTOXICITY OF ADJUVANT TRASTUZUMAB IN EARLY STAGE, HER2-POSITIVE, BREAST CANCER PATIENTS TREATED WITH PRIOR ADJUVANT ANTHRACYLINE-BASED CHEMOTHERAPY
Ratti, Riccardo
Coccorullo, Zaira
Guarneri, Domenico
Colloca, Giuseppe
Venturino, Antonella
Addamo, Gianfranco
Campora, Elisabetta
ANNALS OF ONCOLOGY, 2009, 20
[40] Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
Anthony F. Yu
Roy B. Mukku
Shivani Verma
Jennifer E. Liu
Kevin C. Oeffinger
Richard M. Steingart
Clifford A. Hudis
Chau T. Dang
Breast Cancer Research and Treatment, 2017, 166 : 241 - 247

← 1 2 3 4 5 →